Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 2/20 | 0.56 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.51 |
| ▸ | GPR6 | P46095 | 4/20 | 0.48 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
| ▸ | RET | P07949 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.44 |
| ▸ | RORC | P51449 | 1/20 | 0.43 |
| ▸ | FASN | P49327 | 2/20 | 0.43 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.42 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.42 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6650590 | 0.90 | PPARG (0.49) | PPARGACKR3GPR6FAAHRET | |
| SCHEMBL6645388 | 0.89 | ACKR3 (0.53) | ACKR3GPR6FAAHL3MBTL1RORC | |
| SCHEMBL6645500 | 0.88 | PPARG (0.47) | PPARGACKR3GPR6FAAHRET | |
| SCHEMBL1229935 | 0.79 | MAPK14 (0.50) | PPARGGPR6RETPRKAA2RORC | |
| SCHEMBL6489230 | 0.78 | PRKAA2 (0.47) | PPARGACKR3GPR6FAAHRET | |
| SCHEMBL6646623 | 0.78 | FAAH (0.49) | ACKR3GPR6FAAHL3MBTL1RORC | |
| SCHEMBL6646088 | 0.76 | FAAH (0.47) | ACKR3GPR6FAAHRORCALDH1A1 | |
| SCHEMBL1140493 | 0.76 | DDR2 (0.48) | PPARGRETPRKAA2FASNMAPT | |
| SCHEMBL31037434 | 0.75 | NPC1 (0.58) | ALDH1A1MAPT | |
| SCHEMBL29256601 | 0.75 | NPC1 (0.58) | ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040133008-A1 | Amide compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-07-08 | — | — | US | disclosed |
| WO-2004039795-A2 | AMIDE COMPOUNDS FOR THE TREATMENT OF HYPERLIPIDEMIA | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040133008-A1 | Amide compounds | APOB, APOL1, LDLR | PPARG 427/4885ACKR3 1199/4885GPR6 1809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.